Problems associated with erythropoietin receptor determination on tumor cells
- 1 January 2008
- book chapter
- Published by Springer Nature
- p. 103-115
Abstract
No abstract availableKeywords
This publication has 50 references indexed in Scilit:
- Weighing the Hazards of Erythropoiesis Stimulation in Patients with CancerNew England Journal of Medicine, 2007
- A “classical” homodimeric erythropoietin receptor is essential for the antiapoptotic effects of erythropoietin on differentiated neuroblastoma SH-SY5Y and pheochromocytoma PC-12 cellsCellular Signalling, 2007
- Preclinical studies of erythropoietin receptor expression in tumour cells: Impact on clinical use of erythropoietic proteins to correct cancer-related anaemiaEuropean Journal of Cancer, 2007
- Pleiotropic effects of erythropoietin in neuronal and vascular systemsCurrent Medical Research and Opinion, 2006
- Erythropoietin inhibits apoptosis in breast cancer cells via an Akt-dependent pathway without modulating in vivo chemosensitivityMolecular Cancer Therapeutics, 2006
- Chemosensitization by erythropoietin through inhibition of the NF-κB rescue pathwayOncogene, 2004
- Autocrine erythropoietin signaling inhibits hypoxia-induced apoptosis in human breast carcinoma cellsCancer Letters, 2004
- Erythropoietin has an anti‐myeloma effect – a hypothesis based on a clinical observation supported by animal studiesEuropean Journal of Haematology, 2004
- Erythropoietin stimulates proliferation of human renal carcinoma cellsKidney International, 2000
- Autocrine regulation of erythropoietin gene expression in human hepatocellular carcinoma cellsLife Sciences, 1995